David Turkaly

Citizens | Healthcare

David Turkaly is an analyst from Citizens specializing in the Healthcare sector. Ranked #517 out of 4771 analysts, they have issued 18 stock ratings with a success rate of 97.61% and an average return of 25.57%.

With 18 ratings to date, David Turkaly is beginning to establish credibility in the Healthcare sector. They have achieved a success rate of 97.61% and an average return of 25.57%, highlighting promising potential as their track record develops further.

#517

Out of 4771

18

Total Ratings

+97.61%

Success Rate

+25.57%

Average Return

Recent Ratings Analysis

SYK

Aug 03, 2026

Target

$400.00

Current

$270.01

Performance

-20.86%

David Turkaly rated SYK as Market Outperform on Aug 03, 2026, setting a price target of 400. The stock has underperformed, dropping 20.86% despite the bullish target of 400.

AXGN

Jul 30, 2026

Target

$55.00

Current

$41.85

Performance

1.21%

On Jul 30, 2026, AXGN was given a Market Outperform rating by David Turkaly, with a target price of 55. The stock traded sideways with a 1.21% move, keeping the bullish thesis unresolved.

LNTH

Jun 29, 2026

Target

$115.00

Current

$100.39

Performance

-8.39%

LNTH received a Market Outperform rating from David Turkaly on Jun 29, 2026, aiming for 115. The rating hasn’t played out as hoped, with the stock trading 8.39% below expectations.

MDXG

Apr 30, 2026

Target

$6.00

Current

$4.60

Performance

36.90%

On Apr 30, 2026, David Turkaly published a Market Outperform outlook on MDXG, with a target of 6. Shares gained 36.90%, underscoring the accuracy of the bullish outlook toward 6.

ZBH

Apr 29, 2026

Target

$105.00

Current

$92.44

Performance

15.45%

David Turkaly on Apr 29, 2026 assigned ZBH a Market Outperform rating, with a price target of 105. The Buy call aligned well with market performance, producing a gain of 15.45%.

TELA

Mar 27, 2026

Target

$3.00

Current

$0.91

Performance

35.07%

On Mar 27, 2026, David Turkaly reaffirmed TELA with a Market Outperform rating, targeting 3. The recommendation was supported by strong follow-through as the stock rose from 0.9051 to 0.9051.

APYX

Nov 12, 2025

Target

$8.00

Current

$2.89

Performance

-33.26%

APYX was rated Market Outperform by David Turkaly on Nov 12, 2025, with a price objective of 8. This case shows how bullish projections can fail, with the stock now below 2.89.

KIDS

Oct 10, 2025

Target

$25.00

Current

$21.56

Performance

32.27%

On Oct 10, 2025, David Turkaly initiated coverage on KIDS with a Market Outperform rating and target of 25. The stock’s climb of 32.27% since the call highlights the foresight in the rating.

STE

Apr 10, 2025

Target

$265.00

Current

$212.45

Performance

-2.15%

David Turkaly issued a Market Outperform recommendation for STE on Apr 10, 2025, price target set at 265. The target of 265 remains in play, though confirmation will depend on future moves.

TFX

Apr 02, 2025

Target

—

Current

$132.00

Performance

-6.58%

On Apr 02, 2025, TFX was evaluated by David Turkaly, who gave a Market Perform rating and target of null. The Hold call avoided chasing into subsequent weakness of 6.58%.

IART

Feb 26, 2025

Target

$35.00

Current

$15.54

Performance

-34.15%

David Turkaly rated IART as Market Outperform on Feb 26, 2025, setting a price target of 35. The stock has underperformed, dropping 34.15% despite the bullish target of 35.

SIBN

Feb 25, 2025

Target

$32.00

Current

$18.30

Performance

-0.76%

On Feb 25, 2025, SIBN was given a Market Outperform rating by David Turkaly, with a target price of 32. The stock traded sideways with a -0.76% move, keeping the bullish thesis unresolved.

GMED

Feb 24, 2025

Target

—

Current

$73.56

Performance

-8.07%

GMED received a Market Perform rating from David Turkaly on Feb 24, 2025, aiming for null. The Hold stance proved prudent, with the market softening by 8.07%.

HAE

Feb 07, 2025

Target

$100.00

Current

$101.06

Performance

70.31%

On Feb 07, 2025, David Turkaly published a Market Outperform outlook on HAE, with a target of 100. Shares gained 70.31%, underscoring the accuracy of the bullish outlook toward 100.

SNAP

Jan 29, 2025

Target

$16.00

Current

$5.53

Performance

-52.45%

David Turkaly on Jan 29, 2025 assigned SNAP a Market Outperform rating, with a price target of 16. The call has struggled to gain traction, with shares losing 52.45%.

ENOV

Oct 03, 2024

Target

$62.00

Current

$18.41

Performance

-53.93%

On Oct 03, 2024, David Turkaly reaffirmed ENOV with a Market Outperform rating, targeting 62. Shares slid 53.93% despite the recommendation, highlighting downside risks.

STIM

Aug 14, 2024

Target

$3.00

Current

$3.01

Performance

262.69%

STIM was rated Market Outperform by David Turkaly on Aug 14, 2024, with a price objective of 3. A bullish response from the market helped close the gap of -0.01 to the target.

FNA

May 09, 2024

Target

$20.00

Current

$13.09

Performance

58.67%

On May 09, 2024, David Turkaly initiated coverage on FNA with a Market Outperform rating and target of 20. The stock’s climb of 58.67% since the call highlights the foresight in the rating.

Frequency Asked Questions

Who is David Turkaly?

David Turkaly is an analyst from Citizens specializing in the Healthcare sector.

What is David Turkaly's success rate?

David Turkaly currently has a success rate of +97.61%.

How many ratings has David Turkaly issued?

David Turkaly has issued 18 stock ratings so far.

What is the average return of David Turkaly's calls?

Their stock ratings have generated an average return of +25.57%.

What is David Turkaly's ranking?

David Turkaly is ranked #517 out of 4771 analysts.

What types of ratings does David Turkaly give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow David Turkaly?

You can follow David Turkaly by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by David Turkaly?

Their latest rating was a Buy on SYK issued on 2026-08-03.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep